Literature DB >> 7296754

Experimental in vivo cross-resistance of vinca alkaloid drugs.

R Maral, C Bourut, E Chenu, G Mathe.   

Abstract

In human therapy, an absence of cross-resistance has been observed between vincristine and vindesine in patients receiving polychemotherapy whilst, in our experimental in vivo studies, such a cross-resistance has been found between Vinca alkaloids. Further studies are required to explain this discrepancy.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7296754     DOI： 10.1007/bf00258480

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  12 in total

1.  Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

2.  Vindesine. A short review of preclinical and first clinical data.

Authors:  R W Dyke; R L Nelson; W P Brade
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Treat Rev       Date:  1980-09       Impact factor: 12.111

4.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.

Authors:  R K Johnson; M P Chitnis; W M Embrey; E B Gregory
Journal:  Cancer Treat Rep       Date:  1978-10

Review 6.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

7.  A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.

Authors:  P Mangeney; R Z Andriamialisoa; N Langlois; Y Langlois; P Potier
Journal:  J Org Chem       Date:  1979-10-01       Impact factor: 4.354

8.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

9.  A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.

Authors:  W Krivit; J Anderson; R Chilcote; A Pyesmany; R Chard; D Hammond
Journal:  Am J Pediatr Hematol Oncol       Date:  1980

10.  Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.

Authors:  G Mathé; J L Misset; F De Vassal; J Gouveia; M Hayat; D Machover; D Belpomme; J L Pico; L Schwarzenberg; P Ribaud; M Musset; C Jasmin; L De Luca
Journal:  Cancer Treat Rep       Date:  1978-05
View more
  6 in total

1.  A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.

Authors:  Shih-Hung Yang; Chia-Chi Lin; Zhong-Zhe Lin; Yun-Long Tseng; Ruey-Long Hong
Journal:  Invest New Drugs       Date:  2010-09-01       Impact factor: 3.850

Review 2.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 3.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.

Authors:  R Rahmani; F Guéritte; M Martin; S Just; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Pharmacokinetics of navelbine after oral administration in cancer patients.

Authors:  X J Zhou; P Boré; S Monjanel; Z Sahnoun; R Favre; A Durand; R Rahmani
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.